INT J CANCER 润色咨询

INTERNATIONAL JOURNAL OF CANCER

出版年份：暂无数据 年文章数：9003 投稿命中率： 开通期刊会员，数据随心看

出版周期：Semimonthly 自引率：2.5% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109014, encodeId=60d0210901435, content=是, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Jan 06 06:40:04 CST 2023, time=2023-01-06, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104983, encodeId=5dfa2104983d0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>审稿人还是挺专业的，提的意见对我的工作有很大扩展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 20:56:52 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2100640, encodeId=15bd210064083, content=Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3695520733, createdName=ms3000000777454716, createdTime=Tue Nov 15 12:44:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240989, encodeId=13411240989c0, content=秒拒，编辑直接告知文章接受率&lt;20%,建议转投他刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307d8291747, createdName=ms8000000418182147, createdTime=Thu Aug 25 17:58:16 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-08-23 ms2000002114558983

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤;微生物
    经验分享：3.24咨询是否接收散稿；
    3.28回复感兴趣，欢迎投稿；
    3.31投稿；
    4.4under review;
    4.27major revisions；
    6.20修回；
    6.21外审；
    7.13major revisions；
    8.11修回后决定；
    8.15接收。
    过程很艰辛，审稿人很专业，要求比较高。

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109014, encodeId=60d0210901435, content=是, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Jan 06 06:40:04 CST 2023, time=2023-01-06, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104983, encodeId=5dfa2104983d0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>审稿人还是挺专业的，提的意见对我的工作有很大扩展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 20:56:52 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2100640, encodeId=15bd210064083, content=Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3695520733, createdName=ms3000000777454716, createdTime=Tue Nov 15 12:44:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240989, encodeId=13411240989c0, content=秒拒，编辑直接告知文章接受率&lt;20%,建议转投他刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307d8291747, createdName=ms8000000418182147, createdTime=Thu Aug 25 17:58:16 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-04-08 ms9000000300158487

    偏重的研究方向：tumor microenironment
    经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了

    4

    展开4条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109014, encodeId=60d0210901435, content=是, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Jan 06 06:40:04 CST 2023, time=2023-01-06, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104983, encodeId=5dfa2104983d0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>审稿人还是挺专业的，提的意见对我的工作有很大扩展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 20:56:52 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2100640, encodeId=15bd210064083, content=Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3695520733, createdName=ms3000000777454716, createdTime=Tue Nov 15 12:44:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240989, encodeId=13411240989c0, content=秒拒，编辑直接告知文章接受率&lt;20%,建议转投他刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307d8291747, createdName=ms8000000418182147, createdTime=Thu Aug 25 17:58:16 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-11-12 capoex

    投稿命中率:25.0
    偏重的研究方向：实体肿瘤
    经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109014, encodeId=60d0210901435, content=是, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Jan 06 06:40:04 CST 2023, time=2023-01-06, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104983, encodeId=5dfa2104983d0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>审稿人还是挺专业的，提的意见对我的工作有很大扩展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 20:56:52 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2100640, encodeId=15bd210064083, content=Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3695520733, createdName=ms3000000777454716, createdTime=Tue Nov 15 12:44:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240989, encodeId=13411240989c0, content=秒拒，编辑直接告知文章接受率&lt;20%,建议转投他刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307d8291747, createdName=ms8000000418182147, createdTime=Thu Aug 25 17:58:16 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2023-02-18 1475fbf4m67暂无昵称 来自上海

    偏重的研究方向：Cancer
    经验分享：请问这个杂志接收生信和试验结合的临床文章嘛

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109014, encodeId=60d0210901435, content=是, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Jan 06 06:40:04 CST 2023, time=2023-01-06, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104983, encodeId=5dfa2104983d0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>审稿人还是挺专业的，提的意见对我的工作有很大扩展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 20:56:52 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2100640, encodeId=15bd210064083, content=Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3695520733, createdName=ms3000000777454716, createdTime=Tue Nov 15 12:44:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240989, encodeId=13411240989c0, content=秒拒，编辑直接告知文章接受率&lt;20%,建议转投他刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307d8291747, createdName=ms8000000418182147, createdTime=Thu Aug 25 17:58:16 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2023-01-06 刘煜 来自山东省

    是

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109014, encodeId=60d0210901435, content=是, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Jan 06 06:40:04 CST 2023, time=2023-01-06, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104983, encodeId=5dfa2104983d0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>审稿人还是挺专业的，提的意见对我的工作有很大扩展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 20:56:52 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2100640, encodeId=15bd210064083, content=Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3695520733, createdName=ms3000000777454716, createdTime=Tue Nov 15 12:44:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240989, encodeId=13411240989c0, content=秒拒，编辑直接告知文章接受率&lt;20%,建议转投他刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307d8291747, createdName=ms8000000418182147, createdTime=Thu Aug 25 17:58:16 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-12-08 yousuosaki 来自海南省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向：mutational signature
    经验分享：2022.09.02 submitted
    2022.09.04 under evaluation
    2022.09.12 under review
    2022.09.20 under evaluation
    2022.09.21 under review
    2022.10.20 awaiting decision
    2022.10.25 major revision
    2022.11.19 resubmission
    2022.11.21 under review
    2022.12.2 under evaluation
    2022.12.6 under review
    2022.12.7 awaiting decision
    2022.12.8 accepted
    审稿人还是挺专业的，提的意见对我的工作有很大扩展

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109014, encodeId=60d0210901435, content=是, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Jan 06 06:40:04 CST 2023, time=2023-01-06, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104983, encodeId=5dfa2104983d0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>审稿人还是挺专业的，提的意见对我的工作有很大扩展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 20:56:52 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2100640, encodeId=15bd210064083, content=Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3695520733, createdName=ms3000000777454716, createdTime=Tue Nov 15 12:44:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240989, encodeId=13411240989c0, content=秒拒，编辑直接告知文章接受率&lt;20%,建议转投他刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307d8291747, createdName=ms8000000418182147, createdTime=Thu Aug 25 17:58:16 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-11-15 ms3000000777454716

    Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109014, encodeId=60d0210901435, content=是, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Jan 06 06:40:04 CST 2023, time=2023-01-06, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104983, encodeId=5dfa2104983d0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>审稿人还是挺专业的，提的意见对我的工作有很大扩展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 20:56:52 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2100640, encodeId=15bd210064083, content=Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3695520733, createdName=ms3000000777454716, createdTime=Tue Nov 15 12:44:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240989, encodeId=13411240989c0, content=秒拒，编辑直接告知文章接受率&lt;20%,建议转投他刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307d8291747, createdName=ms8000000418182147, createdTime=Thu Aug 25 17:58:16 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-07-04 ay

    6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109014, encodeId=60d0210901435, content=是, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Jan 06 06:40:04 CST 2023, time=2023-01-06, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104983, encodeId=5dfa2104983d0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>审稿人还是挺专业的，提的意见对我的工作有很大扩展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 20:56:52 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2100640, encodeId=15bd210064083, content=Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3695520733, createdName=ms3000000777454716, createdTime=Tue Nov 15 12:44:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240989, encodeId=13411240989c0, content=秒拒，编辑直接告知文章接受率&lt;20%,建议转投他刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307d8291747, createdName=ms8000000418182147, createdTime=Thu Aug 25 17:58:16 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2021-09-04 凶巴巴恰北北怪兽

    7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好

    16

    展开16条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109014, encodeId=60d0210901435, content=是, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Fri Jan 06 06:40:04 CST 2023, time=2023-01-06, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104983, encodeId=5dfa2104983d0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>审稿人还是挺专业的，提的意见对我的工作有很大扩展, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 20:56:52 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2100640, encodeId=15bd210064083, content=Under evaluation一周之后状态变成Draft已经一天了，是格式不对么？但是通讯没收到杂志社邮件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3695520733, createdName=ms3000000777454716, createdTime=Tue Nov 15 12:44:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230473, encodeId=504012304e3e3, content=6.25投稿，6.30没有外审拒稿。Thank you for submitting your manuscript “” to the International Journal of Cancer. The Editors have now considered the paper with regards to its suitability for publication in the International Journal of Cancer. The International Journal of Cancer has been receiving an increasing number of good manuscripts and less than 20% of the papers submitted to the journal can be published. New submissions are judged according to the novelty and impact of the work in the field of cancer research and to their scope and priority for our journal in face of the large number of competing submissions. Unfortunately, your present work did not receive a high enough priority for further consideration. Thank you for entrusting us with the evaluation of your research. I hope that our decision in this instance does not dissuade you from submitting your work to the International Journal of Cancer in the future. Sincerely yours, Prof. Christoph Plass Editor-in-Chief International Journal of Cancer intjcanc@dkfz.de, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c09e2145377, createdName=ay, createdTime=Mon Jul 04 14:34:51 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240989, encodeId=13411240989c0, content=秒拒，编辑直接告知文章接受率&lt;20%,建议转投他刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307d8291747, createdName=ms8000000418182147, createdTime=Thu Aug 25 17:58:16 CST 2022, time=2022-08-25, status=1, ipAttribution=)]
    2022-08-25 ms8000000418182147

    秒拒，编辑直接告知文章接受率<20%,建议转投他刊

    0

共500条页码: 2/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分